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THE COVID-19 VACCINE DILEMMA 
DORIT RUBINSTEIN REISS* 
COVID-19 continues to lead to large numbers of deaths, harms, and financial costs. 
Without an effective vaccine, those will continue.  The pressure to find a vaccine is high; 
and that pressure places a risk on the safeguards in place to assure that vaccines are safe 
and effective will be ignored.  The United States has an extensive apparatus to oversee 
vaccine safety before and after licensing, including multiple federal committees and several 
monitoring systems, and that apparatus gave us, in 2020, an extraordinarily safe vaccine 
supply.  This Article explains the different pressures that push for and against using the 
same apparatus for COVID-19 vaccines, including the extensive harms from the disease on 
one side and the need for a vaccine that is, in fact, safe and effective on the other.  It examines 
the options for speeding up the process without sacrificing too much oversight.  It examines 
which “shortcuts” are reasonable, which may be challenging, and which are bad ideas.  
Finally, it addresses three messaging challenges—overselling, under-sharing, and 
responding to misinformation—and suggests how to handle them.  
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INTRODUCTION 
On June 4, 2020, Science Magazine published an article stating that 
“Operation Warp Speed,” a public–private partnership started by the federal 
government with the purpose of developing an effective vaccine, “selected five 
experimental COVID-19 vaccines to fast–track through testing and, 
potentially, mass–scale production.”1  Such news surprised top scientists 
involved with the White House-led program.2  The article went on to explain 
that Operation Warp Speed will give chosen companies “access to additional 
government money, help in running clinical trials and financial and logistical 
support for a manufacturing base that is being built even before it is clear which 
if any of the vaccines in development will work.”3  It is possible—and 
important—to speed up testing and production of COVID-19 vaccines 
without undermining trust in them.  But it has to be done right, in a way that 
does not cast doubt on the process.  The aforementioned article captured fears 
of many observers concerned about politically motivated corner cutting in 
developing COVID-19 vaccines.  While there are several good reasons to want 
a vaccine as soon as possible, there are real concerns about rushing a vaccine 
to market in the wrong way.  The “wrong way” could include forgoing input 
from experts or oversight bodies, lacking a basis on scientifically sound criteria, 
politicizing certain choices, or lacking transparency in the process.4  
Undermining trust could also increase hesitancy towards using the vaccine 
even by people who are usually pro-vaccine.  The events described in the 
article were examples of speeding up vaccine development done wrong.  It 
does not have to be this way.   
In less than six months, COVID-19 dramatically changed our world, both 
globally and in the United States.  COVID-19 has killed over two hundred 
and fifty thousand Americans, hospitalized many more, shut down the 
economy, and led most states to issue stay-at-home orders for a period of 
 
1. Jon Cohen, Top U.S. Scientists Left Out of White House Selection of COVID-19 Vaccine Short List, 
SCI. MAG. (June 4, 2020, 7:45 PM), https://www.sciencemag.org/news/2020/06/top-us-
scientists-left-out-white-house-selection-covid-19-vaccine-shortlist/ (giving the name 
“Operation Warp Speed” to a government project aimed to speeding up vaccine development); 
see also Fact Sheet: Explaining Operation Warp Speed, U.S. DEP’T OF HEALTH & HUM. SERVS., https://
www.hhs.gov/about/news/2020/06/16/fact-sheet-explaining-operation-warp-speed.html 
(Nov. 30, 2020) (noting the agencies and firms working on the operation). 
2. Cohen, supra note 1. 
3. Id. 
4. See Ezekiel J. Emanuel & Paul A. Offit, Could Trump Turn a Vaccine Into a Campaign Stunt?, 
N.Y. TIMES (June 8, 2020), https://nyti.ms/3h1k5CO (concerning politicizing the process of 
releasing a coronavirus vaccine). 
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time.5  Citizens, experts, and policymakers continue to struggle to deal with 
this disease.  The long-term solution for all of the challenges that accompany 
COVID-19 is a vaccine that allows individuals to develop immunity to the 
virus without being infected.6  Generally, the vaccine development process 
takes many years, but waiting years or decades will cause many more deaths 
and extensive harms.7  The pressure to get a vaccine to market quickly is 
immense, as the costs of allowing COVID-19 to go unchecked are very 
high— but speeding up the process comes with real risks.8  The United States 
has a very robust system for testing vaccines and monitoring their safety.9  The 
current system has resulted in an extraordinarily safe vaccine supply thus far.10  
This Article examines not only what can or should be done to speed up 
COVID-19 vaccine development but also what should not be done.11  
 
5. Maps & Trends: Mortality Analyses, JOHNS HOPKINS UNIV. & MED., 
https://coronavirus.jhu.edu/data/mortality (last visited Dec. 2, 2020); Robert O. Bonow et al., 
Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality, 5 J. AM. MED. 
ASS’N CARDIOLOGY 751, 751 (2020); Martin S. Andersen, Early Evidence on Social Distancing 
in Response to Covid-19 in the United States 2  (June 25, 2020) (unpublished manuscript), 
https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID3635547_code1834306.pdf?abstractid
=3569368&mirid=1. 
6. Stewart Lyman, If Pharma Helps Quench the Covid-19 Pandemic, What Will it Want in 
Return?, STAT NEWS (Apr. 21, 2020), https://www.statnews.com/2020/04/21/vaccine-
quenches-covid-19-what-will-pharma-want-in-return/; Lois Privor-Dumm et al., The Success 
of a Covid-19 Vaccine Will Hinge on its Delivery, STAT NEWS (Apr. 25, 2020), https://www.statne
ws.com/2020/04/25/success-covid-19-vaccine-hinge-on-delivery/.  
7. The usual process takes over a decade.   Cecile Artaud et al., Vaccine Development: From 
Preclinical Studies to Phase 1/2 Clinical Trials,  in MALARIA CONTROL & ELIMINATION 165, 
165–66 (Frédéric Ariey et al. eds., 2019). 
8. Julie Steenhuysen, As Pressure for Coronavirus Vaccine Mounts, Scientists Debate Risks of 
Accelerated Testing, REUTERS (Mar. 11, 2020, 7:07 AM), https://www.reuters.com/article/us-
health-coronavirus-vaccines-insight/as-pressure-for-coronavirus-vaccine-mounts-scientists-
debate-risks-of-accelerated-testing-idUSKBN20Y1GZ. 
9. U.S. Vaccine Safety – Overview, History, and How it Works, U.S. CTRS. FOR DISEASE 
CONTROL & PREV., https://www.cdc.gov/vaccinesafety/ensuringsafety/history/index.html 
(Sept. 9, 2020). 
10.  Ensuring Vaccine Safety, U.S. CTRS. FOR DISEASE CONTROL & PREV., 
https://www.cdc.gov/vaccinesafety/ensuringsafety/index.html (July 1, 2020) (“The United 
States has the safest, most effective vaccine supply in its history.  The . . . vaccine safety system 
ensures that vaccines are as safe as possible.”). 
11. For some discussions on the topic, see Ezekiel J. Emanuel et al., Fair Allocation of Scarce 
Medical Resources in the Time of Covid-19, 382 NEW ENG. J. MED. 2049, 2049–50 (2020); Thomas J. 
Bollyky et al., The Equitable Distribution of Covid-19 Therapeutics and Vaccines, 323 J. AM. MED. ASS’N 
2462 (2020).  Another important question is how vaccines will be distributed once licensed since 
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Pressures may lead to errors and failures in three spheres: oversight failures, 
ethical failures, and messaging failures.  With COVID-19, pressures derive 
both from the harms of the virus itself and from the presidential election since 
political factors impose pressures of their own.12  These combined pressures 
could enable unjustified corner cutting in the testing process for the vaccine 
and allow oversight bodies to ignore problems even after the vaccine is 
licensed.  At the same time, in the pandemic context, nonaction also carries 
real costs, and in such times, there is no cost-free or risk-free choice.  
Policymakers need to consider both sides of this dilemma when making 
choices.   Other concerns include messaging failures, such as overly optimistic 
messaging that creates unrealistic expectations, as well as messaging that 
creates concerns throughout the public that the vaccine produced will be 
unsafe—even when that is not the reality.   
While the reactions to COVID-19 are specific to this pandemic, this 
general scenario—a tension between a dangerous, harmful disease and the 
potential risks of not going through the full process of overseeing and vetting 
a vaccine—is not new and will likely recur.13  The general tensions described 
in this piece, and the considerations around choosing between options, will 
be relevant in future crises.   
This Article proceeds in four parts.  Part I explains the regulatory 
framework governing vaccine licensing and monitoring in routine times.  
Part II explains the dilemma COVID-19 poses for vaccine development.  
Part III sets out possible scenarios addressing regulatory concerns and ethical 
concerns.  Part IV addresses potential messaging pitfalls and their harms.  I 
then conclude that while we should make adjustment to allow for fast 
development where we can, we need to make sure we are not sacrificing 
safety or effectiveness in the process.   
I. REGULATORY FRAMEWORK 
Vaccines are classified as biologics under the Public Health Service Act of 
1944.14  In practice, this means that vaccines are subject to both the 
 
at least, at first, there will likely be limited quantities available.  That topic is beyond this article; 
it deserves its own treatment.   
12. Aimee Picchi, Could Trump Push a Vaccine Through Before Election Day? CBS NEWS (Sept. 
11, 2020, 3:04 PM), https://www.cbsnews.com/news/coronavirus-vaccine-process-fda-politica
l-pressure/. 
13. Brit Trogen et al., Adverse Consequences of Rushing a SARS-CoV-2 Vaccine Implications for 
Public Trust, 323 J. AM. MED. ASS’N 2460 (2020).  
14. 42 U.S.C. § 262(i).  Biologics are defined as a “virus, therapeutic serum, toxin, antitoxin, 
vaccine, blood, blood component or derivative, allergenic product or analogous product or 
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requirements of the Public Health Service Act and of the Food and Drug 
Administration (FDA), which applies to licensing drugs under the Food, 
Drug and Cosmetics Act.15  Marketing a biologic requires the sponsor, 
usually a pharmaceutical company, to submit a Biologics License 
Application,16 which requires showing that the biologic is “safe, pure, potent 
and effective.”17  The FDA interprets the Public Health Safety Act to require 
that biologics—like other drugs—undergo “controlled clinical 
investigations” in humans.18  To get to human clinical trials, the sponsor must 
submit an Investigational New Drug (IND) application to the FDA.19  An 
IND application requires that “preclinical studies should be sufficient to rule 
out overt toxicity and identify potential toxic effects that might occur during 
the clinical trial.” 20  The FDA “has 30 days” to object after the agency 
receives an IND submission or the clinical “trial may proceed.”21  The IND 
application usually requires evidence of safety and immunogenicity (ability 
to elicit an immune response—that the vaccine candidate works) in animals, 
as well as other data.22  The vaccine then undergoes three stages of clinical 
trials, described by the FDA:23 
Pre-marketing (pre-licensure) vaccine clinical trials are typically done in three phases, 
as is the case for any drug or biologic.  Initial human studies, referred to as Phase 1, 
are safety and immunogenicity studies performed in a small number of closely 
monitored subjects.  Phase 2 studies are dose-ranging studies and may enroll hundreds 
of subjects. Finally, Phase 3 trials typically enroll thousands of individuals and provide 
 
arsphenamine or derivative of arsphenamine . . .  applicable to the prevention, treatment, or 
cure of a disease or condition of human beings.”  Kathleen R. Kelleher, Note, FDA Approval of 
Generic Biologics: Finding a Regulatory Pathway, 14 MICH. TELECOMM. TECH. L. REV. 245, 247 (2007).  
15. Edward L. Korwek, Human Biological Drug Regulation: Past, Present, and Beyond the Year 
2000, 50 FOOD & DRUG L.J. (SPECIAL ISSUE) 129 (1995); Kelleher, supra note 14 at 248.  
16. 42 U.S.C. § 262(a)(1)(A).  
17. Tam Q. Dinh, Potential Pathways for Abbreviated Approval of Generic Biologics under Existing 
Law and Proposed Reforms to the Law, 62 FOOD & DRUG L.J. 77, 84 (2007). 
18. Id.; see also U.S. CTRS. FOR DISEASE CONTROL & PREVENTION, THE JOURNEY OF 
YOUR CHILD’S VACCINE (2018), https://www.cdc.gov/vaccines/parents/infographics/journ
ey-of-child-vaccine-h.pdf (describing the three phases of clinical trials researchers use to test 
new vaccines). 
19. 21 C.F.R. § 312.20(a). 
20. Valerie Marshall & Norman W. Baylor, Food and Drug Administration Regulation and 
Evaluation of Vaccines, 127 PEDIATRICS S23, S26 (Supp. 2011). 
21. Id. at S27.  
22. Vaccine Development - 101, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/vaccine
s-blood-biologics/development-approval-process-cber/vaccine-product-approval-process 
(Nov. 20, 2020).  
23. Id. 
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the critical documentation of effectiveness and important additional safety data 
required for licensing.24 
The completed trials are then submitted to the FDA’s Center for Biologics 
Evaluation and Research (CBER), where a “multidisciplinary FDA reviewer 
team (medical officers, microbiologists, chemists, biostatisticians, etc.)” 
reviews the evidence.25  If the team gives the go ahead, the material is 
submitted to the FDA’s Vaccines and Related Biological Products Advisory 
Committee (VRBPAC), which advises the FDA about the vaccine’s “safety 
and effectiveness.”26  Since one of the aspects that separates biologic licensing 
from drug licensing is that for biologics the manufacturing plant is also 
licensed, during the review period the manufacturing plant and process of 
producing the vaccine is also subject to inspection and review.27  Normally, 
this takes time.28  
 
Table 1: Vaccine Development Timeline, an Estimate29  
Time Period Stage Description 
“Month 0-24” (This 
can also take many 
years). 
“Preclinical” During this period, scientists study the 
pathogen to decide what type of vaccine 
to do.  They may choose to focus on the 
 
24. Id.  
25. Id.; see also Marshall & Baylor, supra note 20, at S23, S27. 
26. Vaccine Development - 101, supra note 22; see also Marshall & Baylor, supra note 20 at, S28. 
27. Marshall & Baylor, supra note 20 at, S27.  
28. Ana Santos Rutschman, The Vaccine Race in the 21st Century, 61 ARIZ. L. REV. 729, 731 
(2019) (noting that the time that inspection and review takes is not only an issue during a 
pandemic; generally, this means that vaccines are not ready when the threat of a new 
pathogen is highest). 
29. This table heavily draws on a blog post created by an anonymous blogger with 
pharmaceutical experience and, with the permission of the author, with some information I 
added.  I have made changes to the language for clarity, but by and large, this is drawn from: 
Coronavirus Vaccine Development – It’s Going to Take a Long Time, SKEPTICAL RAPTOR: BLOG (Apr. 19, 
2020), [hereinafter Vaccine Development Timeline] https://www.skepticalraptor.com/skepticalrapto
rblog.php/coronavirus-vaccine-development-its-going-to-take-a-long-time/.  Note that this 
description assumes the virus or bacterial causing the disease has been identified—a necessary 
first step, which in many cases takes additional time - and that the timeline is likely “optimistic.”  
Id.  For example, the rotavirus vaccine took twenty-six years to develop.  Sabin Institute Honors Paul 
Offit, MD, Vaccine Champion, CHILD. HOSP. OF PHILA. RSCH. INST.: CORNERSTONE BLOG (May 
2, 2018), https://www.research.chop.edu/cornerstone-blog/sabin-institute-honors-paul-offit-
md-vaccine-champion; Greg Johnson, Q&A with Paul Offit, PENN TODAY (May 14, 2015), 
https://penntoday.upenn.edu/2015-05-14/interviews/qa-paul-offit.  
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part of the virus or bacteria, or on the 
entire organism.  Scientists are looking 
for the best way to trigger an immune 
response without causing the disease or 
causing harm to humans.  They then 
need to develop an animal model in 
which they can test the vaccine 
candidate to see if produces immunity in 
a safe manner.  The hope is that the 
model will be sufficiently relevant to 
allow scientists to draw conclusions for 
the effects in humans; though, those 
conclusions will be tentative until human 
testing is done.    
“Month 24” “IND 
application” 
Once the preclinical studies are 
completed, the “sponsoring 
organization” (which is usually an 
experienced vaccine manufacturer) 
submits an IND application to FDA.  The 
application is reviewed by the Center for 
Biologics Evaluation and Research 
(CBER) in FDA.  If it is approved, the 
company can prepare for—and then 
begin—clinical trials in humans.  




The vaccine manufacturing company 
applies to an Institutional Review Board 
(IRB) for permission to test the drug in 
human.  Then, the product undergoes 
three stages of clinical trials:  
“Phase 1 clinical trials usually include 
around 100 healthy patients ( . . . no 
comorbidities and generally lack any 
chronic health conditions).  This study is 
not usually randomized or blinded, as 
there is only one group, those that receive 
the vaccine.”  Phase 1 clinical trials are 
intended to alert you to safety problems 
or signals, and help determine vaccine 
dose.  Many studies terminate after Phase 
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I because of safety concerns.  But at this 
point, you do not have good information 
about safety or effectiveness. 
“Phase 2 clinical trials usually include 
around 200-300 patients.  This study is a 
randomized, double-blind trial . . . .”  It 
provides initial indications of effectiveness 
and safety, which help researchers 
determine if there is justification to move 
to the next phase. 
“Phase 3 clinical trials, sometimes called 
pivotal studies, include around 2–3 
thousand patients” though for vaccines 
there could be tens of thousands of 
subjects.  “These studies must be 
randomized, double-blinded, [and] 
placebo-controlled ( . . . [or using] a 
standard of care control).” 
The results of “[P]hase 2 and 3 clinical 
trials”, when showing success, “are often 
published in peer-reviewed journals.” 
“Month 60-78” “[R]egulatory 
review and 
approval” 
Once the testing of the vaccine candidate 
is complete, the company manufacturing 
it can—if the results justify it—submit a 
Biologics License Application (BLA) to 
CBER.  It will simultaneously develop a 
manufacturing plan and prepare to build 
manufacturing facilities with enough 
capacity to produce the needed amount 
of vaccine.  These facilities, in turn, need 
also be approved by the FDA. 
 
Vaccine development takes time for a number of reasons.  It can take time 
to set up clinical trials and get volunteers.30  For example, although Moderna 
 
30. Vaccine Development Timeline, supra note 29. 
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opened its clinical trial in late July, by September 11, 2020, they only had 
23,497 participants out of the intended 30,000.31  Other obstacles include  
reaching the broad diversity needed for a clinical trial.32  Then, data needs 
to be collected by closely monitoring participants over a long enough period, 
and analyzed in multiple ways, to ensure accuracy.33  Normally, exposing 
participants to the virus intentionally is unethical, so researchers need to wait 
long enough for natural exposure to happen in a large enough segment of 
participants.34  As discussed below, one of the approaches considered to 
expedite COVID-19 vaccines is to intentionally expose volunteers to the 
virus.35  Further, to see whether immunity is more than transient, the trial 
will have to proceed for multiple months.36  To give some examples, 
Gardasil—a vaccine against the Human Papilloma Virus—involved Phase 
III trials that followed participants for about three years.37  For rotavirus, 
infants were followed for a year.38  There are problems that may arise and 
consequently slow down the process.  Sometimes vaccines need to be 
reworked.  When a vaccine does not produce intended results, scientists need 
to go back to the beginning and find a solution, if possible.  It is also important 
to remember that there is no guarantee any vaccine candidate will pass 
clinical trials; in fact, clinical trials fail over 80% of the time.39  In the case of 
COVID-19 vaccines, there are over one hundred in development and tens 
 
31. Brian Orelli, Moderna Slowed Enrollment in Its Phase 3 Coronavirus Vaccine Clinical Trial, 
MOTLEY FOOL (Sept. 13, 2020, 12:13 PM), https://www.fool.com/investing/2020/09/13/mo
derna-slowed-enrollment-in-its-phase-3-coronavir/. 
32. Jenae Barnes, A Black Participant in Moderna’s Covid-19 Vaccination Trial: Trust the Vaccine, 
ABC NEWS (Aug. 30, 2020, 3:05 PM), https://abcnews.go.com/Health/black-participant-
modernas-covid-19-vaccination-trial-trust/story?id=72654085. 
33. Vaccine Development Timeline, supra note 29. 
34. Id.  
35. See infra Part III, at 56–57.  
36. Smriti Mallapaty and Heidi Ledford, COVID-vaccine Results are on the Way – and Scientists’ 
Concerns are Growing, NATURE (Sept. 25, 2020) https://www.nature.com/articles/d41586-020-
02706-6.  
37. See generally Suzanne M. Garland et al., Quadrivalent Vaccine Against Human Papillomavirus 
to Prevent Anogenital Diseases, 356 NEW ENG. J. MED. 1928 (2007); The FUTURE II Study 
Group, Quadrivalent Vaccine Against Human Papillomavirus to Prevent Anogenital Diseases, 356 NEW 
ENG. J. MED. 1915, 1915–16, 1924 (2007). 
38. Timo Vesikari et al., Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant 
Rotavirus Vaccine, 354 NEW ENG. J. MED. 23, 26 (2006). 
39. See JA DiMasi et al., Trends in Risks Associated with New Drug Development: Success Rates 
for Investigational Drugs, 87 CLINICAL PHARMA. & THERAPEUTICS 272, 272–74, 276–77 
(2010), (observing that the success rate in clinical trials in the United States was 16% 
between 1999–2004). 
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that have started clinical trials in humans.40  The data suggests that we will 
have more than one successful vaccine candidate, at some point. 
Licensing is not the end of the process or scrutiny.  First, production is 
subject to continuing scrutiny—the FDA exercises some oversight over 
“lot[s]”, or batches, of vaccines.41  Historical experience supports this 
requirement: one of the worst vaccine disasters in the United States was the 
result of a mishandled manufacturing process.42  In the Cutter incident, 
nearly 200 children were paralyzed and ten died because a polio vaccine 
that should have contained an inactivated virus included a live, virulent 
virus instead.43   Close oversight of the manufacturing process helps prevent 
similar tragedies.  Another concern is the potential contamination of 
vaccines, as there are several instances of contamination in the past.44  Each 
lot of the licensed vaccine is subject to testing.45  Licensed vaccine 
production facilities need to be “inspected at least every 2 years.”46  In 
addition, multiple oversight mechanisms exist to oversee vaccine safety after 
licensing (like VRBPAC does before licensing).47  These mechanisms are not 
only used to discover issues that may have been missed during trials but also 
to find issues trials are too small to discover.48  While clinical trials include 
up to tens of thousands of people, they would not identify a problem that is 
as rare as, say, one per a hundred thousand.49  
 
40. Ewen Callaway, The Race for Coronavirus Vaccines: A Graphical Guide, NATURE (Apr. 28, 
2020), https://www.nature.com/articles/d41586-020-01221-y; see also Draft Landscape of 
COVID-19 Candidate Vaccines, WORLD HEALTH ORG., https://www.who.int/publications/m/
item/draft-landscape-of-covid-19-candidate-vaccines Dec 2, 2020).  
41. Vaccine Development - 101, supra note 22; Dinh, supra note 17. 
42. Paul A. Offit, The Cutter Incident, 50 Years Later, 352 NEW ENG. J. MED. 1411, 1411 (2005). 
43. Id.; Trogen et al., supra note 13; Johnson, supra note 29. 
44. See generally John Petricciani et al., Adventitious Agents in Viral Vaccines: Lessons Learned from 
4 Case Studies, 42 BIOLOGICALS 223 (2014). 
45. Marshall & Baylor, supra note 20, at S23, S28–29 (2011); Theresa M. Finn, U.S. FDA 
Requirements for Human Vaccine Product Safety and Potency Testing, 5 PROCEDIA VACCINOLOGY 137, 
139 (2011).  
46. Marshall & Baylor, supra note 20, at S29.  
47. Id. at S28–29.  
48. Id. at S29.  
49. Steven Black, The Importance of Active Surveillance in the Assessment of Vaccine Safety 1 
CCDC WKLY. 26, 26 (2019) (“[W]ith rare events, such as Guillain–Barre Syndrome, 
detecting a 2-fold increased relative risk with a background incidence of 1/100,000 would 
require a study of more than 4.7 million people.  This would be impossible in a clinical trial, 
but by using large clinical datasets, however, such an association can be assessed.”). 
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However, continuous monitoring can uncover these rare problems.50  In 
the United States, the Department of Health and Human Services (HHS) 
uses a combination of methods to monitor vaccine safety.51  These methods 
include oversight by federal expert committees and maintaining 
sophisticated databases for researchers to analyze and discover problems.52  
First, the Advisory Committee on Immunization Practices (ACIP), made up 
of fifteen experts in “infectious diseases, pediatrics, internal medicine, family 
medicine, virology, immunology, public health, preventive medicine, vaccine 
research and policy, economics and cost-effectiveness”—as well as a 
“consumer representative”—monitors vaccines, usually starting about two 
years before licensure.53  ACIP makes recommendations about the vaccine 
schedule for both children and adults and reviews vaccine safety data during 
its meetings, which take place three times a year, and continuously through 
its work groups.54  For COVID-19 vaccines, a work group started in April 
2020 made progress on a vaccine.55  Also meeting three times a year is the 
National Vaccine Advisory Committee (NVAC), whose duties include to 
“[s]tudy and recommend ways to encourage the availability of an adequate 
supply of safe and effective vaccination products in the United States,” and 
to “[r]ecommend research priorities and other measures the Director of the 
National Vaccine Program, an office in HHS should take to enhance the 
safety and efficacy of vaccines.”56  NVAC includes fifteen public members, 
“selected from individuals who are engaged in vaccine research or the 
manufacture of vaccines, or who are physicians, members of parent 
organizations concerned with immunizations, representatives of State or 
 
50. See Vaccine Safety Scientific Agenda, U.S. DEPT. OF HEALTH & HUM. SERVS. 1, 3−5, 
https://www.hhs.gov/vaccines/national-vaccine-plan/vaccine-safety-scientific-agenda/in
dex.html (June 10, 2019) (explaining systems for vaccine safety, including VAERS, VSD, 
and PRISM). 
51. Id. at 1−4. 
52. Id.  
53. See Jean Clare Smith, The Structure, Role, and Procedures of the U.S. Advisory Committee on 
Immunization Practices (ACIP), 285 VACCINE A68, A68, A71 (2010). 
54. Id. at A70–A72.  See generally ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES 
POLICIES AND PROCEDURES 4–5, 7, U.S. CTRS. FOR DISEASE CONTROL & PREVENTION (2018), 
https://www.cdc.gov/vaccines/acip/committee/downloads/Policies-Procedures-508.pdf. 
55. See Beth Bell, Work Group Chair, U.S. Ctrs. for Disease Control & Prevention, 
Introduction for Presentation on ACIP COVID-19 Vaccines Work Group 2–3, 8 (June 24, 
2020), https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-06/COVID-
05-Bell-508.pdf (discussing mission and founding of Work Group, and introducing presenters 
on COVID-19 vaccine development, considerations, and next steps).  
56. NVAC Charter, U.S. DEP’T OF HEALTH & HUM. SERVS. https://www.hhs.gov/vaccin
es/nvac/charter/index.html (last visited Dec. 2, 2020). 
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local health agencies or public health organizations,” and two representatives 
of the vaccine industry.57  Finally, among the responsibilities of the Advisory 
Committee on Childhood Vaccines (ACCA) are the duties to “advise the 
Secretary . . . regarding the need for childhood vaccination products that 
result in fewer or no significant adverse reactions.”58  The Committee also 
collects data on vaccines’ adverse reactions and suggests research related to 
it.59  The ACCA committee’s members are “three . . . health professionals” 
with “expertise in the health care of children, the epidemiology, etiology, and 
prevention of childhood diseases, and the adverse reactions associated with 
vaccines, of whom at least two shall be pediatricians,” “three members from 
the general public,” at least two “legal representatives of children who have 
suffered a vaccine-related injury or death,” and “three . . . attorneys,” at least 
one specializing in representing vaccine injury cases, and one who represents 
vaccine manufacturers.60  Since these committees are all subject to the 
Federal Advisory Committee Act, meetings and materials are public and 
easily accessible, allowing for public scrutiny of proceedings.61   
In addition to advisory committees, there are four large computerized 
systems that collect data on vaccine risks.62  These include the Vaccine Adverse 
Events Reporting System (VAERS), a passive reporting system that anyone 
can report to, designed to provide early warnings of issues.63  Although, 
VAERS has real limits as a passive monitoring system, it has successfully 
caught issues in the past.  For example, VAERS has caught a rare (1:10,000), 
serious side effect of the first Rotavirus vaccine to be licensed in the United 
States, which was confirmed in an independent investigation.64  The other 
three monitoring systems are active monitoring systems.  The Vaccine Safety 
Datalink (VSD) is a collaboration between the Centers for Disease Control and 
 
57. Id. 
58. CHARTER: ADVISORY COMMISSION ON CHILDHOOD VACCINES, U.S. DEP’T. OF 
HEALTH & HUM. SERVS. 1 (2020), https://www.hrsa.gov/sites/default/files/hrsa/advisory-
committees/vaccines/accv-charter.pdf. 
59. Id.; see also Efthimios Parasidis, Recalibrating Vaccination Laws, 97 B.U. L. REV. 2153, 
2227 (2017) (suggesting the Committee should be used more).  
60. Advisory Comm’n on Childhood Vaccines Charter, supra note 58. 
61. 5 U.S.C. app. §§ 2, 10.  
62. See generally Vaccine Safety, U.S. DEP’T. OF HEALTH & HUM. SERVS, https://www.vacci
nes.gov/basics/safety (Feb. 2020) (identifying components of vaccine monitoring system).  
63. Vaccine Adverse Event Reporting System (VAERS), U.S. CTRS. FOR DISEASE CONTROL & 
PREVENTION, https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/ (Sept. 
11, 2020). 
64. Jason Schwartz, The First Rotavirus Vaccine and the Politics of Acceptable Risk, 90 MILBANK 
Q. 278, 285–289 (2012).  Although Prof. Schwartz’ account is cautionary, it highlights that the 
problems with the vaccine were raised—and followed on—within a few months of its use.   Id. 
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Prevention (CDC) and healthcare organizations covering millions of people.  
It includes both constant active monitoring of signals, by comparing on an 
ongoing basis people who have received a vaccine and those who have not.  
VSD also allows researchers to do in-depth analyses of specific issues.65  Many 
studies are done using VSD data, including a 2018 whitepaper on studying the 
safety of the entire schedule.66  The Post-Licensure Rapid Immunization 
Safety Monitoring System (PRISM), another large active system, is part of the 
FDA Sentinel System—a system designed to monitor medical products by 
tracking health insurance claims.67  PRISM covers 171 million people, 
allowing for studies larger than other systems.68 
Finally, the Clinical Immunization Safety Assessment Project (CISA) 
allows providers to submit queries and get an expert evaluation about 
specific patients, including evaluations of whether a problem is vaccine-
related or whether an existing condition is a contraindication to a vaccine.69  
CISA also conducts direct research on vaccine safety for specific issues and 
special populations.70   
Besides these mechanisms in HHS, research is conducted in other parts of 
the United States government: 
The Department of Defense (DoD) and U.S. Department of Veterans Affairs (VA) have 
systems to monitor vaccine safety and do vaccine safety research.  The National 
Institutes of Health (NIH) and the Office of Infectious Disease and HIV/AIDS Policy 
(OIDP) also support ongoing research on vaccines and vaccine safety.71 
In other words, extensive institutional arrangements for monitoring vaccine 
safety exist in the United States in relation to routine vaccines.  These 
 
65. Vaccine Safety Datalink (VSD), U.S. CTRS. FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/ (Aug. 24, 2020). 
66. JASON GLANTZ ET AL., NAT’L CTR. FOR EMERGING & ZOONOTIC INFECTIOUS 
DISEASES, WHITE PAPER STUDYING THE SAFETY OF THE CHILDHOOD IMMUNIZATION 
SCHEDULE FOR THE VACCINE SAFETY DATALINK (2016), https://www.cdc.gov/vaccinesafety/
pdf/whitepapersafety_web.pdf. 
67. See Vaccine Safety, supra note 62; see also Vaccines, Blood, & Biologics Assessments, 
SENTINEL, https://www.sentinelinitiative.org/vaccines-blood-biologics/assessments/ (last 
visited Dec. 2, 2020). 
68. Public Workshop: The Sentinel Post-Licensure Rapid Immunization Safety Monitoring (PRISM) 
System, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/vaccines-blood-biologics/workshops
-meetings-conferences-biologics/public-workshop-sentinel-post-licensure-rapid-immunization-
safety-monitoring-prism-system (Sept. 18. 2018). 
69. Clinical Immunization Safety Assessment (CISA) Project, U.S. CTRS. FOR DISEASE CONTROL 
& PREVENTION, https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.h
tml (July 20, 2020). 
70. Id.  
71. Vaccine Safety, supra note 62. 
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arrangements result in a very high level of safety.72  Summarizing that data, 
the National Academies of Sciences, Engineering, and Medicine concluded 
that “[v]accines are extremely safe.  They have many health benefits and few 
side effects.”73  
II. COVID-19 AND THE CHALLENGE TO VACCINES 
Normally, vaccine development takes years.  But between February 2020 
and the end of September 2020, over a million people worldwide died from 
COVID-19.74  By December 2, 2020, deaths in the United States topped 
269,000.75  By many indications, this is an undercount of deaths.76  Millions 
have been infected by the virus.77  Looking at the United States alone, as of 
the week ending November 7, 2020, just under 21 million people have 
applied for unemployment insurance, and during the week ending 
 
72. Sarah Geoghegan et al., Vaccine Safety: Myths and Misinformation, 11 FRONTIERS 
MICROBIOLOGY, Mar. 2020, at 5; Frank DeStefano et al., Principal Controversies in Vaccine Safety 
in the United States, 69 CLINICAL INFECTIOUS DISEASES 726 (2019).  But see Parasidis, supra note 
59, at 2210, 2223–2225, 2227 (concluding systems are insufficient).  Note, however, that the 
article downplays the role of the active monitoring systems described above, id. at 2223–2225, 
and only briefly mentioned one of the four advisory committees described here. Id. at 2210 
fn.460, 2217, 2227. 
73. Vaccines are Safe, NAT’L ACADS. OF SCI., ENG’G & MED., https://sites.nationalacademies
.org/BasedOnScience/vaccines-are-safe/index.htm (last visited Dec. 2, 2020); see also FE Andre 
et al., Vaccination Greatly Reduces Disease, Disability, Death and Inequity Worldwide, 86 BULLETIN OF THE 
WORLD HEALTH ORGANIZATION [WHO] 140, 140 (2008), https://www.ncbi.nlm.nih.gov/pm
c/articles/PMC2647387/pdf/07-040089.pdf (“[I]ndependent experts and WHO have shown 
that vaccines are far safer than therapeutic medicines.  Modern research has spurred the 
development of less reactogenic products, such as acellular pertussis vaccines and rabies vaccines 
produced in cell culture.  Today, vaccines have an excellent safety record and most “vaccine 
scares” have been shown to be false alarms.”). 
74. Emiliano Rodrigues Mega, COVID has Killed More than One Million People.  How Many More 
Will Die? NATURE (Sept. 30, 2020), https://www.nature.com/articles/d41586-020-02762-y.  
75. CDC Covid Data Tracker United States Covid-19 Cases and Deaths by State, U.S. CTRS. FOR 
DISEASE CONTROL & PREVENTION, https://www.cdc.gov/coronavirus/2019-ncov/cases-
updates/cases-in-us.html (Dec. 2, 2020); Coronavirus Resource Center, JOHNS HOPKINS UNIV. & 
MED., https://coronavirus.jhu.edu/us-map (last visited Dec. 2, 2020).  
76. Stephanie Pappas, How COVID-19 Deaths are Counted, SCI. AM. (May 19, 2020), 
https://www.scientificamerican.com/article/how-covid-19-deaths-are-counted1/. 
77. Coronavirus Disease (Covid-19) Situation Report – 127, WORLD HEALTH ORG., (May 26, 
2020, 10:00 AM), https://www.who.int/docs/default-source/coronaviruse/situation-report
s/20200526-covid-19-sitrep-127.pdf?sfvrsn=7b6655ab_8. 
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November 21, 2020 778,000 filed initial claims.78  Since the beginning of the 
crisis, hundreds of thousands of small business have closed and others are at 
risk of closure.79  Children are out of school and daycare, imposing burdens 
on families and depriving children of a variety of important social goods.80  
The costs are not evenly distributed, exacerbating existing inequalities.81  The 
harms, also, disproportionally (though not exclusively) fall on minority 
groups.82  The economic impacts are not limited to the United States 
economy—many other countries are struggling as well.83 
 The virus, both directly and through diverse disruptive impacts, poses real 
risks to people’s health and lives.84  For individuals who already live on the 
margins of poverty, losing a job means they may not be able to cover all their 
basic needs.85  Some may face the loss of their home, and homelessness—or 
poverty generally—worsens health outcomes.86  Not taking measures to 
 
78. See Press Release, U.S. Dep’t of Labor, Unemployment Insurance Weekly Claims 1, 
4, 6 (Nov. 25, 2020), https://www.dol.gov/ui/data.pdf.  
79.  STEVEN HAMILTON, THE HAMILTON PROJECT, POLICY PROPOSAL 2020-14, FROM 
SURVIVAL TO REVIVAL: HOW TO HELP SMALL BUSINESSES THROUGH THE COVID-19 CRISIS 
4 (Brookings Inst. 2020), https://www.brookings.edu/wp-content/uploads/2020/09/PP_Ham
ilton_Final.pdf.; MICHAEL POWE & MATTHEW WAGNER, NAT’L MAIN ST. CTR., THE IMPACT 
OF COVID-19 ON SMALL BUSINESSES: FINDINGS FROM MAIN STREET AMERICAN’S SMALL 
BUSINESS SURVEY 3–4 (2020), https://higherlogicdownload.s3.amazonaws.com/NMSC/390e
0055-2395-4d3b-af60-81b53974430d/UploadedImages/Resource_Center/COVID_19/NM
SC57_MSA_COVID19IMAPCTSURVEY_F.pdf.  
80. See NAT’L ACADS. OF SCI., ENG’G, & MED., REOPENING K-12 SCHOOLS DURING THE 
COVID-19 PANDEMIC: PRIORITIZING HEALTH, EQUITY, AND COMMUNITIES 25–31 (2020); 
Russel M. Viner et al., School Closure and Management Practices During Coronavirus Outbreaks Including 
Covid-19: A Rapid Systematic Review, in 4 LANCET CHILD & ADOLESCENT HEALTH 397, 398 (2020). 
81. Emily A. Benfer & Lindsay F. Wiley, Health Justice Strategies to Combat COVID-19: 
Protecting Vulnerable Communities During a Pandemic, HEALTHAFFAIRS: BLOG (Mar. 19, 2020), 
https://www.healthaffairs.org/do/10.1377/hblog20200319.757883/full/. 
82. Monica Webb Hooper et al., COVID-19 and Racial/Ethnic Disparities, 323 J. AM. MED. 
ASS’N 2466, 2466 (2020); Cato T. Laurencin & Aneesah McClinton, The COVID-19 Pandemic: 
A Call to Action to Identify and Address Racial and Ethnic Disparities, 7 J. RACIAL ETHNIC HEALTH 
DISPARITIES 398, 398–400 (2020).  
83. Peterson K. Ozili & Thankom Arun, Spillover of COVID-19: Impact on the Global 
Economy 1–3, 5–14, 20 (Mar. 27, 2020) (unpublished manuscript), https://papers.ssrn.com/sol
3/Delivery.cfm/SSRN_ID3584485_code1996195.pdf?abstractid=3562570&mirid=1; COVID-
19’s Historic Economic Impact, In the U.S. and Abroad, JOHNS HOPKINS UNIV.: HUB (Apr. 16, 2020), 
https://hub.jhu.edu/2020/04/16/coronavirus-impact-on-european-american-economies/. 
84. Martin McKee & David Stuckler, If the World Fails to Protect the Economy, COVID-19 
Will Damage Health Not Just Now but Also in the Future, 26 NATURE MED. 640 (2020). 
85. Benfer & Wiley, supra note 81. 
86. Id. 
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contain spread would not necessarily spare the economy: people would 
respond to an uncontrolled pandemic by taking actions that would harm the 
economy.87  The high costs of the pandemic and its containment—measured 
in lives, health, and economic harms—put pressure on policymakers and 
scientists to find a quick solution.88  The long-term solution, experts agree, is 
having a safe, effective vaccine that will ideally prevent COVID-19 from 
infecting people and spreading throughout the population.89  The public and 
business interests are also anxiously awaiting a vaccine.90   Going through the 
regular process means a long wait for the vaccine.  Understandably, 
policymakers—and citizens—are concerned about that long wait.91  
Policymakers correctly point out that while rushing a vaccine through the 
process has risks, so does waiting until the usual testing is complete.92  Letting 
COVID-19 rage unchecked will kill many and cause additional harms through 
economic consequences.93  On the other hand are the costs of having an unsafe 
vaccine.  First, an unsafe vaccine can directly harm people.  During previous 
vaccine scandals, like the Cutter Incident or the 1976 swine flu episode, people 
died or were paralyzed by a vaccine.94  There is also some risk that a COVID-
19 vaccine could predispose recipients to a more severe case of the disease.95  
Dr. Douglas Green of St. Jude’s Research Hospital explained: 
In 1966, a large trial of a vaccine for Respiratory Syncytial Virus (RSV) found that the 
immunized cohort actually faired [sic] significantly worse upon infection.  Additionally, 
many worry that the same may occur with some SARS-CoV2 vaccines. . . . There are 
 
87. Sergio Correia et al., Pandemics Depress the Economy, Public Health Interventions Do 
Not: Evidence from the 1918 Flu 1–2, 12–13, 15–16 (June 5, 2020) (unpublished manuscript), 
https://papers.ssrn.com/sol3/Delivery.cfm/SSRN_ID3624939_code2423067.pdf?abstractid
=3561560&mirid=1; Pierre-Olivier Gourinchas, Flattening the Pandemic and Recession Curves, in 
MITIGATING THE COVID ECONOMIC CRISIS: ACT FAST AND DO WHATEVER IT TAKES  31, 35, 
38 (Richard Baldwin & Beatrice Weder di Mauro eds., 2020). 
88. Stanley A. Plotkin & Arthur Caplan, Extraordinary Diseases Require Extraordinary Solutions, 
38 VACCINE 3987, 3897 (2020). 
89. Id.  
90. See Sarah Zhang, A Vaccine Reality Check, ATLANTIC (July 25, 2020, 7:56 PM) 
https://www.theatlantic.com/health/archive/2020/07/covid-19-vaccine-reality-check/6 
14566/. 
91. Moncef Slaoui & Matthew Hepburn, Developing Safe and Effective Covid Vaccines — 
Operation Warp Speed’s Strategy and Approach, 383 NEW ENG. J. MED. 1701 (Oct. 29, 2020). 
92. Bijayeeta Deb et al., Current Global Vaccine and Drug Efforts Against COVID-19: Pros and 
Cons of Bypassing Animal Trials, 45 J. BIOSCIENCES 82 (2020). 
93. Id. 
94. Trogen et al., supra note 13. 
95. Douglas R. Green, Editorial, SARS-CoV2 Vaccines: Slow is Fast, SCI. ADVANCES (May 22, 
2020), https://advances.sciencemag.org/content/early/2020/05/22/Sciadv.abc7428.full. 
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potential reasons why an immune response to a vaccine can predispose an individual to a 
worse outcome upon infection.  One is the phenomenon of antibody-dependent 
enhancement (ADE).  In this effect, antibodies that bind to the virus also bind to antibody 
receptors on cells, facilitating uptake and infection of the cell bearing the receptors.  ADE 
was observed for vaccines against Dengue, Ebola, and HIV.  As recently as 2017, a large-
scale efficacy trial of a Dengue vaccine resulted in ADE in vaccinated children. 
Troublingly, ADE was also seen in vaccines for a feline coronavirus.  There is also 
evidence for ADE in SARS-CoV. Studies show that rodent and human antibodies to the 
S protein enhance infection in vitro.  However, several small preclinical studies of a 
SARS-CoV vaccine in rhesus monkeys failed to observe evidence of ADE.96   
Testing must assure that a vaccine is not worse than the disease and does 
not predispose the recipient to worse cases going forward.  But that comparison 
is not as straightforward as it may seem.  Every vaccine is approved on a risk–
benefit analysis: are the risks greater than the benefits?  All vaccines carry at 
least a theoretical risk of a severe allergic reaction, which if untreated can be 
fatal; though, that risk is extremely small.97  The polio vaccine used in the 
United States between 1961–1997  (and a few years afterward, since the 
process of transition was gradual) was the oral polio vaccine (OPV).98  OPV 
causes paralysis in recipients in about one in 2.4 million doses.99  However, the 
benefits of the vaccine were considered high enough to justify the risk.100  For 
a COVID-19 vaccine, too, the question is not simply whether it will have any 
rare hidden risks, but whether the potential of rare hidden risks is higher than 
the risks of not giving the vaccine.  That comparison depends on several 
factors.  During the pandemic, when cases are high and the effects of the 
pandemic are severe and visible, we may tolerate a higher risk than when the 
 
96. Id. (“One SARS-CoV2 vaccine, employing inactivated virus, was tested in several large 
cohorts of rhesus monkeys, with substantial efficacy and no evidence of ADE.  While this is 
clearly encouraging, the need to ensure that any vaccine is, indeed, safe is of vital importance.”). 
97. Michael M. McNeil et al., Risk of Anaphylaxis After Vaccination in Children and Adults, 137 
J. ALLERGY & CLINICAL IMMUNOLOGY 868, 871, 874–75, 877 (2016) (noting that the risk is 
around one per million overall, and for some vaccines the risk is purely theoretical). 
98. Poliomyelitis Prevention in the United States: Introduction of a Sequential Vaccination Schedule of 
Inactivated Poliovirus Vaccine Followed by Oral Poliovirus Vaccine; Recommendations of the Advisory 
Committee on Immunization Practices (ACIP), U.S. CTRS. FOR DISEASE CONTROL & PREVENTION 
(Jan. 24, 1997), https://www.cdc.gov/mmwr/preview/mmwrhtml/00046568.htm. 
99. Id.  
100. Notice to Readers: Recommendations of the Advisory Committee on Immunization Practices: 
Revised Recommendations for Routine Poliomyelitis Vaccination, U.S. CTRS. FOR DISEASE CONTROL 
& PREVENTION (July 16, 1999), https://www.cdc.gov/mmwr/preview/mmwrhtml/mm48
27a4.htm.  
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case rate declines.101  But this, too, needs to be examined more closely.  First, 
the risks of the vaccine may not be equally distributed with the risks of the 
disease.  For example, the risks of COVID-19, though they exist in every age 
group, vary—the risk of direct death or severe outcomes increases with age.102  
At the same time, there is growing evidence of a special inflammatory 
syndrome in children caused by COVID-19.103  The highest risks associated 
with a new vaccine, however, may be in a group for whom the risks of 
COVID-19 are low.  Is it ethical to impose a created risk on one group to 
protect another?  Incomplete testing means we may not know who bears the 
risk, or the nature and severity of uncommon risks.  Further, scientists, 
policymakers, and members of the public do not treat the risks of vaccines as 
equivalent to the risks of the disease.  As mentioned above, in 1998, a rotavirus 
vaccine with a 1:10,000 risk of a severe side effect was taken off the market 
because that risk was deemed too high to be acceptable in a vaccine—even 
though the risks of the disease were higher than 1:10,000 severe harm.104  
Giving a vaccine to a healthy person is not the same as treating someone who 
is sick, and the standard is not simply whether the risks are higher than the 
benefits.  Since modern routine childhood vaccines have extremely low risks, 
our safety expectations from vaccines are high.  We have already seen several 
examples where rush led to potential harm in the context of the COVID-19 
pandemic.  For example, the FDA authorized hydroxychloroquine (HCQ) 
after the medication was touted as a cure for COVID-19, even though there 
was insufficient evidence for doing so.105  The FDA pulled the aforementioned 
 
101. See Frank Destefano et al., Vaccine Safety, in PLOTKIN’S VACCINES 1584, 1595–96 
(Stanley A. Plotkin et al. eds., 7th ed. 2018). 
102. Dale Fisher & David Heymann, Q&A: The Novel Coronavirus Outbreak Causing Covid-
19, 18 BMC MED. 57 (2020). 
103. See Jennifer Couzin-Frankel, Doctors Race to Understand Rare Inflammatory Condition 
Associated with Coronavirus in Young People, SCI. MAG. (May 21, 2020, 4:10 PM), https://www.scienc
emag.org/news/2020/05/doctors-race-understand-rare-inflammatory-condition-associated-
coronavirus-young-people; Crystal Phend, Targeting Immune Responses in Kids’ COVID-19 
Inflammatory Disorder, MEDPAGE TODAY (May 21, 2020), https://www.medpagetoday.com/infec
tiousdisease/covid19/86614.  The CDC labeled it “multisystem inflammatory syndrome in 
children,” and pointed out that most children recover with treatment.  See for Parents: Multisystem 
Inflammatory Syndrome in Children (MIS-C) associated with Covid-19, U.S. CTRS. FOR DISEASE 
CONTROL & PREVENTION, https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/ch
ildren/mis-c.html (May 20, 2020), 
104. Withdrawal of Rotavirus Vaccine Recommendation, U.S. CTRS. FOR DISEASE CONTROL & 
PREVENTION (Nov. 5, 1999), https://www.cdc.gov/mmwr/preview/mmwrhtml/mm4843a5.htm.  
105. See Jinoos Yazdany & Alfred H.J. Kim, Use of Hydroxychloroquine and Chloroquine During 
the COVID-19 Pandemic: What Every Clinician Should Know, 172 ANNALS INTERNAL MED. 754, 
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authorization after increasing amounts of data suggested no benefit from using 
HCQ to treat COVID-19.106  The initial recommendation, in the meantime, 
was not harmless.  HCQ as a treatment had risks—and touting it as a cure for 
COVID-19 created availability-related risks for those who need it to treat 
diseases for which HCQ actually helps.107  Panic prescribing is a real risk 
associated with the pandemic, as is the risk of panic approval of vaccines with 
negative results.108  Political pressures facing the administration during an 
election year exacerbate such risks.109  These pressures already led to clear and 
extensive political interference in public health agencies, and raise concerns 
about hasty vaccine approval.110  An unsafe vaccine creates harms that are 
ethically—and publicly—unacceptable.  This can result in a lack of trust 
towards other vaccines, which can lead to lower vaccination rates and 
attendant risks of outbreaks for other diseases.111  Additionally, unsafe vaccines 
negatively affect the willingness to comply with other public health 
recommendations that are dependent on trust.  
III. OUR OPTIONS 
There are multiple ways to increase the speed of vaccine development.  
None are perfect or unproblematic; some are reasonable, some ethically 
 
754–55 (2020); Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of 
Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of COVID-19 in 
Certain Hospitalized Patients, U.S. FOOD & DRUG ADMIN. (Apr. 27, 2020), https://www.fda.gov
/media/136537/download. 
106. Letter from Dinese M. Hinton, Chief Scientist, U.S. Food & Drug Admin., to Gary 
L. Disbrow, Dir., Biomedical Advanced Rsch. & Dev. Auth., U.S. Dep’t of Health & Hum. 
Servs. 1–2 (June 15, 2020), https://www.fda.gov/media/138945/download; see also Joe Palca, 
FDA Withdraws Emergency Use Authorization for Hydroxychloroquine, NPR (June 15, 2020, 2:30 PM), 
https://www.npr.org/sections/coronavirus-live-updates/2020/06/15/877498151/fda-with
draws-emergency-use-authorization-for-hydroxychloroquine.  
107. Camela Thompson, Life with Lupus: Trump’s Hydroxychloroquine Hype Puts My Treatment 
— and Himself — at Risk, STAT NEWS (May 20, 2020), https://www.statnews.com/2020/05/20/
hydroxychloroquine-trump-hype-jeopardize-supply-may-harm-him/. 
108. Holly Fernandez Lynch et al., ‘Panic Prescribing’ Untested Coronavirus Treatments: A Danger 
to Patients Today and Tomorrow, HEALTHAFFAIRS: BLOG (Mar. 31, 2020), https://www.healthaffair
s.org/do/10.1377/hblog20200330.265604/full/. 
109. Kevin Liptak & Kaitlan Collins, Trump Puts Pressure on FDA for Coronavirus Silver Bullet 
Ahead of Election Day, CNN (Sept. 3, 2020, 9:34 PM) https://www.cnn.com/2020/09/03/politics
/white-house-fda-coronavirus-vaccine/index.html. 
110. Dan Diamond, Trump Officials Interfered with CDC Reports on Covid-19, POLITICO, 
https://www.politico.com/news/2020/09/11/exclusive-trump-officials-interfered-with-cdc-
reports-on-covid-19-412809 (Sept. 12, 2020 11:11 AM). 
111. Trogen et al., supra note 13. 
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challenging, and some outright dangerous.  Dangers come in two varieties: 
some approaches increase the risk of ending with an unsafe or ineffective 
vaccine, a result that does not improve the pandemic situation.  Others do 
not risk the final result but can dramatically increase the risks to trial 
participants.   One caveat: this section focuses on the process before licensing.  
I see no reason to relax the oversight and requirements in place after a 
vaccine is licensed and, indeed, it is particularly important to preserve 
oversight and respect the role of advisory committees in the process and 
assuring transparency towards them.  Oversight mechanisms after licensing 
should carefully monitor any licensed COVID-19 vaccines.  As a final 
preliminary point, it is important to acknowledge the institutional framework 
the Administration put in place to oversee vaccine development.  To 
coordinate the process of vaccine approval, the Administration created 
“Operation Warp Speed.”112  Operation Warp Speed is in charge of 
coordinating between the many actors involved—  
[c]omponents of the Department of Health and Human Services (HHS), including the 
Centers for Disease and Prevention (CDC), the Food and Drug Administration (FDA), 
the National Control Institutes of Health (NIH), and the Biomedical Advanced 
Research and Development Authority (BARDA), and the Department of 
Defense . . .   private firms and other federal agencies, including the Department of 
Agriculture, the Department of Energy, and the Department of Veterans Affairs.113   
I find the title unfortunate, suggesting as it does rushing ahead without 
caution.  However, it is a positive thing to have a government entity 
coordinating something as large as the effort to create and provide vaccines to 
three hundred thousand plus citizens.  The Administration chose a veteran 
military man and a pharmaceutical insider to lead the process.114  Nonprofits 
complained to the HHS Inspector General about the appointment of Dr. 
Slaoui, who has direct investments and roles with a variety of pharmaceutical 
companies.  In July 2020, the Inspector General rejected the complaints, ruling 
Dr. Slaoui can remain in that role.115  Although this choice raises questions 
about the project, other participants are veteran civil servants with extensive 
 
112. Fact Sheet: Explaining Operation Warp Speed, supra note 1.  
113. Id. 
114. See id. (appointing HHS Secretary Alex Azar and Defense Secretary Mark Esper, 
Dr. Moncef Slaoui, and General Gustave F. Perna). 
115. Christopher Rowland, Chief of White House’s ‘Operation Warp Speed’ Vaccine Effort Can 
Keep Investing in Pharma Firms, Under IG Ruling, WASH. POST (July 14, 2020, 08:24 PM), 
https://www.washingtonpost.com/business/2020/07/14/chief-white-houses-operation-
warp-speed-vaccine-effort-can-keep-investing-pharma-firms-under-ig-ruling/. 
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expertise in the area;  like Dr. Peter Marks, who directs the FDA’s CBER.116  
The main concern I see about Operation Warp Speed is not its leadership, but 
the lack of transparency with which, apparently, it has been operating.  This 
will be addressed again later.  
So, what are the options?  A straightforward approach that has been used 
before is to conduct multiple testing phases together.  For example, several 
companies are conducting Phase 1 and Phase 2 trials simultaneously.117  
Overlapping trial stages are not unusual, and there may be good reasons to go 
back and forth.  For example, there may be something that needs testing in a 
smaller, more intensive trial while a large trial is going on.  In addition, as 
mentioned previously, Phase 1 trials do not typically provide a lot of 
information about the vaccine, so combining Phase 1 trials with Phase 2 trials 
may speed up the development process.  Another time-saving approach is to 
prepare large trials early, which is a reasonable and likely uncontroversial step.118 
While an early set up has financial risks, it will not undermine vaccine 
safety or effectiveness.119  As further suggested in an editorial, these could be 
done as “adaptive randomized-controlled” trials:  
These trials can be structured to evaluate multiple vaccine candidates against a 
common control group and can shift enrollment based on which vaccines are most 
promising.  Vaccines would be selected based on their promise in early studies and how 
quickly their manufacturing can be scaled.  With so many patients developing mild or 
no symptoms, clinical trials will need to be large.  But this is the best shot at quickly 
identifying safe and effective vaccines.120 
 
 
116. Trump Administration Announces Framework and Leadership for 'Operation Warp Speed', U.S. DEP’T 
OF HEALTH & HUM. SERVS. (May 15, 2020), https://www.hhs.gov/about/news/2020/05/15/tr
ump-administration-announces-framework-and-leadership-for-operation-warp-speed.html. 
117. Coronavirus Vaccine Trials – Updating Current Studies Across the World, SKEPTICAL RAPTOR: 
BLOG (July 8, 2020), https://www.skepticalraptor.com/skepticalraptorblog.php/coronavirus-
vaccine-trials-updating-current-studies-across-world/.  
118. Arthur Allen, Op-Ed, While the U.S. Rushes to Develop a COVID-19 Vaccine, Here’s What 
Science Tells Us, L.A. TIMES (May 21, 2020, 3:00 AM), https://www.latimes.com/opinion/story/
2020-05-21/coronavirus-vaccine-testing-approval.  For example: 
Under a proposal under discussion by a committee set up by the National Institutes of 
Health, each of four or five experimental vaccines would be tested on about 20,000 trial 
participants with a placebo group of 10,000 for each vaccine.  Some 50 U.S. medical 
centers—and perhaps an equal number overseas—would participate in these trials.  
Id. 
119. Id.  
120. Luciana Borio & Scott Gottlieb, Opinion, A Fast Coronavirus Vaccine, Without Cutting 
Corners, WALL ST. J. (May 31, 2020, 3:47 PM), https://www.wsj.com/articles/a-fast-coronaviru
s-vaccine-without-cutting-corners-11590954444?mod=opinion_lead_pos8. 
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These trials are costly and, when they are government funded, costs that 
usually fall on companies—costs of testing vaccines that may well never make 
it to market—will fall on the taxpayers.121  But in the context of a harmful, 
disruptive pandemic, that may be justified.  That said, these trials need to be 
focused on the best vaccine candidates from a scientific perspective.  Political 
selection of vaccine candidates to be supported by the government—or those 
receiving production support—undermines legitimacy and can directly 
counter the search for a better vaccine.122  In the United States, coordinated 
by Operation Warp Speed, the Biomedical Advanced Research and 
Development Authority (BARDA) is collaborating with three different 
companies—Moderna, Janssen Research (which is part of Johnson & 
Johnson), and AstraZeneca—on clinical trials.123  The trials themselves are 
overseen and regulated by the FDA (with a secondary role to NIH), and 
companies have to work out problems with those agencies.124  Also costly, 
but not controversial from the point of view of safety, is setting up production 
before trials are complete—something suggested both in the United 
Kingdom and in the United States.125  In the United States, BARDA is 
managing the preparation for scaling up production.126  These approaches, 
too, carry an economic risk: preparing for production is costly, and if the 
vaccine candidate in question does not succeed in a clinical trial, the 
investment would have been for nothing.  The investment itself does not, 
 
121. See Fact Sheet: Explaining Operation Warp Speed, supra note 1 (demonstrating that the 
government is funding the private companies). 
122. Emanuel & Offit, supra note 4.  
123. Press Release, U.S. Dep’t of Health & Hum. Servs., HHS Accelerates Clinical Trials, 
Prepares for Manufacturing of COVID-19 Vaccines (Mar. 30, 2020), https://www.hhs.gov/abo
ut/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccine
s.html; Trump Administration’s Operation Warp Speed Accelerates AstraZeneca COVID-19 Vaccine to be 
Available Beginning in October, U.S. DEP’T OF HEALTH & HUM. SERVS. (May 21, 2020), 
https://www.hhs.gov/about/news/2020/05/21/trump-administration-accelerates-astrazenec
a-covid-19-vaccine-to-be-available-beginning-in-october.html.  
124. Marisa Taylor & Robin Respaut, Moderna Spars with U.S. Scientists Over COVID-19 
Vaccine Trials, REUTERS (July 7, 2020, 7:04 AM), https://www.reuters.com/article/us-health-
coronavirus-moderna-exclusive/exclusive-moderna-spars-with-u-s-scientists-over-covid-19-vac
cine-trials-idUSKBN2481EU. 
125. See Ian Sample, UK plans £38m Centre to Start Production of Coronavirus Vaccine, GUARDIAN 
(May 17, 2020, 1:31 PM), https://www.theguardian.com/society/2020/may/17/uk-plans-
38m-centre-to-start-production-of-coronavirus-vaccine (demonstrating the United Kingdom 
approach); Christopher Rowland et al., Even Finding a Covid-19 Vaccine Won’t Be Enough to End the 
Pandemic, WASH. POST (May 11, 2020, 4:16 PM), https://www.washingtonpost.com/business/
2020/05/11/coronavirus-vaccine-global-supply/ (demonstrating the U.S. approach). 
126. See Fact Sheet: Explaining Operation Warp Speed, supra note 1. 
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however, create a risk of an unsafe outcome; though, it can create political 
pressures on the participants and raise the stakes, making it tempting to hide 
bad results.  Such investments should be accompanied by careful oversight 
of the companies whose vaccine candidates are chosen for this support. 
Another potential approach is to permit use through an Emergency Use 
Authorization (EUA) for vaccines that have successfully passed one or more 
stages of trial in some circumstances.127  We can likely expect such requests 
as soon as there is partial robust data that the vaccines in trials work, 
assuming no major safety concerns are discovered because of the level of 
harm the pandemic is causing.  EUA requires a declaration by the HHS 
Secretary that justifies issuing an EUA, following a determination of a 
domestic, military, public health emergency or  material threat.128  The 
Secretary should then consult “(to the extent feasible and appropriate given 
the applicable circumstances) with the Assistant Secretary for Preparedness 
and Response (ASPR), the Director of the National Institutes of Health 
(NIH), and the Director of CDC,” and if the statutory criteria have been met, 
issue the authorization.129 
The criteria to institute an EUA for “an unapproved medical product” are 
where there are: 
(1) Serious or life-threatening illness or condition caused by CBRN agent as set 
forth in HHS declaration; 
(2) Reasonable belief that the product may be effective in diagnosing, treating, or 
preventing the illness or condition caused by the agent (based on totality of scientific data); 
(3) The product’s known and potential benefits outweigh known and potential risks 
when used for disease or condition; and 
(4) There is no adequate approved, available alternative.130 
In February 2020, the HHS Secretary announced an emergency 
surrounding the pandemic, and approved a number of EUA for COVID-19-
related products, including “use of in vitro diagnostics for the detection and/or 
diagnosis of COVID-19 (February 4, 2020), personal respiratory protective 
devices (March 2, 2020), and other medical devices, including alternative 
 
127. See John D. Blum & Jordan Paradise, Public Health Preparedness & Response: An Exercise in 
Administrative Law, 20 DEPAUL J. HEALTH CARE L., June 2018, at 15; Charles G. Kels, Dispensing 
Medical Countermeasures: Emergency Use Authorities and Liability Protections, 13 HEALTH SEC. 139 (2015). 
128. Blum & Paradise, supra note 127, at 15. 
129. U.S. FOOD & DRUG ADMIN., U.S. DEPT’ OF HEALTH & HUM. SERVS., OMB 
CONTROL NO. 0910-0595, EMERGENCY USE AUTHORIZATION OF MEDICAL PRODUCTS AND 
RELATED AUTHORITIES: GUIDANCE FOR INDUSTRY AND OTHER STAKEHOLDERS 6 (2017), 
https://www.fda.gov/media/97321/download. 
130. Id.  
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products used as medical devices (March 24, 2020).”131  We can reasonably 
expect requests for such use of vaccines to start rolling in as soon as the data 
supports them.  This is an approach whose desirability really depends on the 
details.  Vaccines were approved for emergency use before in analogous 
circumstances, though not through an EUA.  For example, a meningococcal 
B vaccine licensed elsewhere, but not in the United States, was used during a 
meningococcal outbreak in several college campuses.132  In 2014–2015, a 
vaccine not yet approved for Ebola was allowed use during an outbreak in 
Africa.133  The vaccine was later approved.134  Both cases involved an outbreak 
of a potentially fatal disease, creating a vivid and visible life-threatening 
emergency.  In the COVID-19 context, an example could be an outbreak 
overwhelming hospitals, which occurred in Italy and New York City, or an 
outbreak in a high-risk environment like a nursing home.135  The legitimacy of 
this approach would also depend on the evidence on the potential benefits 
compared to the potential risks.  The meningococcal B vaccine underwent 
several clinical trials, and was approved—and used—in Europe after enough 
safety data was provided to European regulatory authorities to justify it, and 
 
131. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical 
Device, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/medical-devices/emergency-use-
authorizations-medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authoriz
ations-medical-devices (Aug. 3, 2020). 
132. See Blair Capitano et al., Experience Implementing a University-Based Mass Immunization 
Program in Response to a Meningococcal B Outbreak, in 15 HUM. VACCINES & IMMUNOTHERAPIES 717, 
717 (2019); JoNel Aleccia, Emergency Meningitis Vaccine Will be Imported to Halt Ivy League Outbreak, 
NBC NEWS (Nov. 15, 2013, 4:38 PM), https://www.nbcnews.com/healthmain/emergency-
meningitis-vaccine-will-be-imported-halt-ivy-league-outbreak-2D11603651.  
133. Marissa Fritz, Drug Approval During a Public Health Crisis, REG. REV. (Feb. 11, 2020), 
https://www.theregreview.org/2020/02/11/fritz-drug-approval-during-public-health-crisis/.  
134. Press Release, U.S. Food & Drug Admin., First FDA-Approved Vaccine for the 
Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health 
Preparedness and Response (Dec. 19, 2019), https://www.fda.gov/news-events/press-
announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-
milestone-public-health. 
135. See Carrie Arnold, New York City’s Coronavirus Outbreak is Already Overwhelming Hospitals, 
NEWSCIENTIST (Mar. 31, 2020), https://www.newscientist.com/article/2239247-new-york-
citys-coronavirus-outbreak-is-already-overwhelming-hospitals/#; Sharon Begley, A Plea From 
Doctors in Italy: To Avoid Covid-19 Disaster, Treat More Patients at Home, STAT NEWS (Mar. 21, 2020), 
https://www.statnews.com/2020/03/21/coronavirus-plea-from-italy-treat-patients-at-home/; 
Christina Maxouris, The Most Alarming Coronavirus Numbers in Some States are in Prisons and Nursing 
Homes, CNN (May 7, 2020, 5:47 AM), https://www.cnn.com/2020/05/07/us/coronavirus-
cases-prisons-nursing-homes/index.html. 
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during its use, no new safety concerns emerged.136  The situation for Ebola 
vaccines was different.  A candidate vaccine “was given to at-risk HCW/FLWs 
and at-risk adults and children during the 2014–2016 West African outbreak 
during clinical trials using investigational expanded access protocols,” during 
an efficacy trial in Guinea that showed very high efficacy, justified by the 
severity of the disease.137  During the 2018 and 2019 Ebola outbreaks in the 
Democratic Republic of Congo (DRC), the vaccine was not yet licensed, but 
there was evidence of human trials supporting its use.138  Even in the DRC, 
there was initial hesitancy to use the vaccine in lactating and pregnant 
women—in which the vaccine had not been tested—but the severe risks 
allowed for the vaccine to be used on that population after some debate.139  
Similar questions about use of COVID-19 vaccines in pregnancy may come 
up in the U.S.; the FDA is reluctant to allow trials in pregnant women, and for 
COVID-19 there is no special reason to deviate from that rule.  Though, there 
could be a question about making these vaccines available to that population 
without such trials.140  In other words, emergency use decisions depend not 
only on the existence of an emergency but also on other factors, such as the 
danger from the disease and the already existing data on the vaccine.  Both 
Ebola and meningococcal disease have higher rates of mortality than COVID-
19, and meningococcal has a substantial risk of long-lasting disability even in 
survivors.141  Allowing emergency use of a vaccine with very little safety data 
may be less likely for COVID-19—but that balance may shift as more data 
accumulates.  An obvious concern there is that political pressures will lead to 
approval of emergency use of COVID-19 vaccines where there is no objective  
 
 
136. See Aleccia, supra note 132.  
137. Jenny A. Walldorf et al., Considerations for Use of Ebola Vaccine During an Emergency 
Response, 37 VACCINE 7190, 7195 (2019).  
138. See Second Ebola Vaccine to Complement “Ring Vaccination” Given Green Light in DRC, 
WORLD HEALTH ORG. (Sept. 23, 2019), https://www.who.int/news-room/detail/23-09-
2019-second-ebola-vaccine-to-complement-ring-vaccination-given-green-light-in-drc. 
139. Archana Asundi & Nahid Bhadelia, Making Emergency Use of Experimental Vaccines Safer, 
22 AM. MED. ASS’N  J. OF ETHICS 43, 44 (2020). 
140. See Sam F. Halabi, Zika and the Regulatory Regime for Licensing Vaccines for use During 
Pregnancy, 26 ANN. HEALTH L., Summer 2017, at 20–21. 
141. See U.S. CTRS. FOR DISEASE CONTROL & PREVENTION, EPIDEMIOLOGY AND 
PREVENTION OF VACCINE-PREVENTABLE DISEASES 232, 241 (2015); Ebola Virus Disease, WORLD 
HEALTH ORG. (Feb. 10, 2020), https://www.who.int/news-room/fact-sheets/detail/ebola-
virus-disease; Mortality Analyses, JOHNS HOPKINS CORONAVIRUS RES. CTR., https://coronavir
us.jhu.edu/data/mortality (Dec. 2, 2020, 3:00 AM). 
ACCORD 6.1_REISS_FINAL (DO NOT DELETE) 12/6/2020  4:33 PM 
74 ADMINISTRATIVE LAW REVIEW ACCORD [6:1 
justification.  Arguably, that has already happened with HCQ.142  Whether 
political pressures will lead to emergency use approval in the COVID-19 
context is under extensive debate, the result of which will be unclear when this 
Article goes to publication; but it is a concern.143  Another step that can and 
should occur early on is setting up work groups by the different oversight 
committees once vaccine candidates advance in the trials.  The NIH already 
set up multiple expert committees to work on the different steps.144  An 
executive committee chaired by Dr. Francis Collins, the NIH Director, with a 
co-chair from industry Dr. Paul Stoffels, from Johnson & Johnson, and other 
officials—most from the government but some from pharmaceutical 
companies—lead this effort.145  Under it are four working groups: a Preclinical 
Working Group, a Therapeutics Clinical Working Group, a Clinical Trial 
Capacity Working Group, and a Vaccines Working Group.146  The Vaccines 
Working Group involves pharmaceutical industry members (like Dr. Paula 
Annunziato from Merck and Dr. Tal Zaks from Moderna), public servants 
(like Dr. Douglas Lowy from NIH, and Dr. Peter Marks from the FDA), 
experts from abroad (like Dr. Marco Cavaleri from the European Medicines 
Agency), and academics (like Dr. Beth Bell from the University of Washington, 
who also leads the ACIP working group on COVID-19 vaccines; Dr. Peter 
Hotez from Baylor College of Medicine; and Dr. Paul Offit from the School 
 
142. See John Timmer, FDA Approves the Emergency Use of Chloroquine for COVID-19, 
ARSTECHNICA (Mar. 31, 2020, 4:52 PM), https://arstechnica.com/science/2020/03/fda-
approves-the-emergency-use-of-chloroquine-for-covid-19/; Nicholos Florko, Why was an Obscure 
Federal Bureaucrat Involved in Trump’s Emergency Hydroxychloroquine Authorization?, STAT NEWS (Apr. 
24, 2020), https://www.statnews.com/2020/04/24/why-rick-bright-involved-hydroxychloroq
uine/ (supporting the view that this was unjustified comes from the FDA’s warning against use 
of the drug outside hospital settings, issued less than a month after the emergency use 
authorization); FDA Cautions Against Use of Hydroxychloroquine or Chloroquine for COVID-19 Outside of 
the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems, U.S. FOOD & DRUG ADMIN., 
https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychl
oroquine-or-chloroquine-covid-19-outside-hospital-setting-or (July 1, 2020). 
143. Robert Califf et al., 7 Former FDA Commissioners: The Trump Administration is Undermining 
the Credibility of the FDA, WASH. POST (Sept. 29, 2020, 5:16 PM) https://www.washingtonpost.co
m/opinions/2020/09/29/former-fda-commissioners-coronavirus-vaccine-trump/; Kashmira 
Gander, Trump Must Stop Criticizing Scientists Amid COVID-19 Vaccine Talks: Experts to FDA, 
NEWSWEEK (Sept. 26, 2020, 11:07 AM) https://www.newsweek.com/trump-criticizing-
scientists-coronavirus-vaccine-1534439. 
144. Governance, NAT’L INSTS. OF HEALTH, https://www.nih.gov/research-training/medic
al-research-initiatives/activ/leadership (Sept. 11, 2020).  
145. Id.  
146. Id.  
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of Medicine at the University of Pennsylvania).147  ACIP, as mentioned, set up 
a work group to monitor COVID-19 vaccines in April 2020.148   
 More controversial is the question of whether to allow 
challenge/rechallenge trials.149  Challenge/rechallenge trials involve 
intentionally exposing consenting volunteers who received the vaccine to 
the virus; i.e., injecting them with live COVID-19 virus, under medical 
supervision.150  This technique is advantageous because it does not depend 
on trial participants’ natural exposure to COVID-19—something that 
could take time, especially in areas where the pandemic is under control.  
Several experts strongly recommend challenge/rechallenge trials.151  
Experts point out that there is low risk and high reward when these trials 
are limited to young volunteers, and the benefits of having a vaccine sooner 
are meaningful, including in terms of lives saved.152  The problem, as 
discussed by some of these experts, is that challenge/rechallenge trials ask 
people to “take on risk of severe illness or death.”153  The risk is especially 
high since there is much unknown about COVID-19 and there is no good 
treatment for it.154  Nonetheless, supporters argue these trials will save 
lives.155  Volunteers are lining up for it: a grassroots hotline has signed up 
thousands of people saying they are willing to take the risk (though, such 
 
147. Vaccines Working Group, U.S. NAT’L INSTS. OF HEALTH, https://www.nih.gov/research
-training/medical-research-initiatives/activ/vaccines-working-group (Oct. 20, 2020). 
148. Michael Devitt, Coronavirus Remains Front and Center at June ACIP Meeting, AM. ACAD. OF 
FAM. PHYSICIANS (July 1, 2020, 3:00 PM), https://www.aafp.org/news/health-of-the-public/
20200701acipjunemtg.html. 
149. See Vaccine Challenge Studies—Can it Speed up Coronavirus Vaccine Licensing, SKEPTICAL 
RAPTOR: BLOG (Apr. 20, 2020), https://www.skepticalraptor.com/skepticalraptorblog.php/
vaccine-challenge-studies-can-it-speed-up-coronavirus-vaccine-licensing/.  
150. WORLD HEALTH ORG., KEY CRITERIA FOR THE ETHICAL ACCEPTABILITY OF 
COVID-19 HUMAN CHALLENGE STUDIES 1 (2020) [hereinafter HUMAN CHALLENGE 
STUDIES], https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-
Ethics_criteria-2020.1-eng.pdf?ua=1. 
151. See Plotkin & Caplan, supra note 88; Nir Eyal et al., Human Challenge Studies to Accelerate 
Coronavirus Vaccine Licensure, 221 J. INFECTIOUS DISEASES 1752, 1754 (2020). 
152. See Plotkin & Caplan, supra note 88. 
153. See Eyal et al., supra note 151. 
154. See Shayla Love, People Are Willing to Risk Their Lives for a COVID Vaccine.  Should We 
Let Them?, VICE (Apr. 28, 2020, 7:00 AM), https://www.vice.com/en_us/article/5dm7na/w
hy-intentionally-infecting-people-with-coronavirus-could-be-worth-it; Carolyn Y. Johnson, 
Inside the Extraordinary Race to Invent a Coronavirus Vaccine, WASH. POST (May 3, 2020, 3:57 PM), 
https://www.washingtonpost.com/science/2020/05/02/coronavirus-vaccine/. 
155. See Plotkin & Caplan, supra note 88; Eyal et al, supra note 151 at 1753–54. 
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signing up is no substitute for a fully informed consent process).156  Another 
challenge is that to be ethical, challenge/rechallenge studies should consist 
of healthy, young volunteers—people for whom the risks of COVID-19 are 
low.157  But results from young volunteers would not necessarily teach us 
about the effect of tested vaccines in high-risk populations, such as the 
elderly.  For example, influenza vaccines are much less effective in older 
people than in younger ones, and special variations of influenza vaccines 
are developed for that population.158  Similarly, COVID-19 vaccines 
shown to be effective in young volunteers in challenge/rechallenge studies 
would not signify similar protection of an older population, those that are 
most at risk of harm from the disease.  An additional risk is a setback during 
the challenge/rechallenge trials, such as the death of a participant from 
COVID-19, which could undermine vaccine development—even if the 
vaccine did not directly cause the setback.159  Allowing an EUA based on 
antibody data alone would be highly problematic as well (something which, 
to my knowledge, has not been done before).  At this point, the level of 
antibodies needed to protect against severe COVID-19 and the level that 
protects against infecting others is unclear—the link between antibody 
levels and protection can be complex, and we do not yet have that data for 
COVID-19 vaccines, so acting on that alone can lead to unsupported 
decisions.160  Additionally, the mutation rate and effect of the virus, both of 
which can contribute to a less viable vaccine, is also uncertain.161  If a 
mutation is more infectious than another, the vaccine may not target the 
more virulent form of the virus.162  If the mutation rate is much higher than 
predicted, then a vaccine could be ineffective within a year or even just a 
 
156. See HUMAN CHALLENGE STUDIES, supra note 150 at 1, 5; Ewen Callaway, Hundreds of 
People Volunteer to be Infected with Coronavirus, NATURE (Apr. 22, 2020), https://www.nature.com/a
rticles/d41586-020-01179-x. 
157. See HUMAN CHALLENGE STUDIES, supra note 150, at 3. 
158. Flu & People 65 Years and Older, U.S. CTRS FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/flu/highrisk/65over.htm (Sept. 22, 2020). See generally Vaccine Effectiveness: 
How Well do the Flu Vaccines Work?, U.S. CTRS FOR DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm#older-vaccinated (Jan. 3, 2020). 
159.  Michael Rosenblatt, Human Challenge Trials with Live Coronavirus Aren’t the Answer to a 
Covid-19 Vaccine, STAT NEWS (June 23, 2020), https://www.statnews.com/2020/06/23/challen
ge-trials-live-coronavirus-speedy-covid-19-vaccine (raising this and other points).  
160. See “Immunity Passports” in the Context of Covid-19, WORLD HEALTH ORG. (Apr. 24, 
2020), https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-
context-of-covid-19. 
161. See Ewen Callaway, The Coronovirus is Mutating – Does it Matter?, NATURE (Sept. 16, 
2020), https://www.nature.com/articles/d41586-020-02544-6. 
162. Id. 
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few months.163  Committing too soon to one company producing vaccines 
is just as problematic; we do not know which vaccine candidate will succeed 
in trials.  The UK may have done just that when the government 
committed large sums of money to the production of one candidate vaccine 
that is still in early stages of testing.164  The U.S. government addressed this, 
in part, by choosing four companies with which to partner on the vaccine 
development process.165  But those are still only four, and it is not clear 
whether the government would be willing—or able—to admit error and 
change if needed.  It is important to remember, though, that most vaccines 
do not rely on government money to develop, and that the larger vaccine 
companies can—and are—going ahead with their trials without 
government support.166   Government support allows smaller companies—
who would have had to contract with a large company in order to reach 
testing—to go ahead without that support.167  Still, the choices need to be 
data driven; if a company’s results do not show that its vaccine candidate is 
safe and effective, money devoted to production may be better spent by 
rechanneling it to a more promising candidate.  Similarly, skipping steps in 
testing increases the risks of bad safety outcomes and may undermine the 
use of a plausibly safe vaccine by decreasing trust.168  Going to human 
studies without animal studies would not necessarily mean that the final 
vaccine is unsafe.169  If enough human testing occurs, we can still end up 
with good data on safety and effectiveness.  However, it could mean that 
risks that could be discovered before humans were given the vaccine were 
not discovered—creating additional risks for trial volunteers and presenting 
 
163. Id. 
164. See Sample, supra note 125 (showing the UK’s intent to invest in production). 
165. See Fact Sheet: Explaining Operation Warp Speed, supra note 1. 
166. Press Release, Nat’l Insts. Of Health, NIH to Launch Public-Private Partnership to 
Speed COVID-19 Vaccine and Treatment Options (Apr. 17, 2020) https://www.nih.gov/news
-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatmen
t-options. 
167. See Mark Terry, Moderna and Lonza Enter Large-Scale Manufacturing Deal for Potential 
COVID-19 Vaccine, BIOSPACE (May 1, 2020) https://www.biospace.com/article/moderna-
partners-with-swiss-company-lonza-to-manufacture-covid-19-vaccine/. 
168. See Sara Murray, Even Once a Vaccine Gets Approved, Big Hurdles Remain for Distribution, 
CNN: POLITICS, https://www.cnn.com/2020/07/22/politics/coronavirus-vaccine-distribut
ion-concerns/index.html (noting that a third of Americans surveyed in May 2020 responded 
that they would not get the vaccine even if it was “affordable and widely available”) (July 23, 
2020, 12:58 PM).   
169. Nicoletta Lanese, Researches Fast-Track Coronavirus Vaccine by Skipping Key Animal Testing 
First, LIVE SCI. (Mar. 13, 2020), https://www.livescience.com/coronavirus-vaccine-trial-no-
animal-testing.html (noting that one of the vaccine candidates skipped animal trials). 
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an opportunity for vaccine opponents who seek to frame all vaccines as 
unsafe.  Finally, a major problem to avoid is lack of transparency.   
Oversight and advisory committees involved in the vaccine process—the 
regular committee, and those created to focus on a COVID-19 vaccine—
need full, transparent information to do their job of meaningful oversight 
and help lead us to a vaccine that is, in fact, safe and effective.  In the June 
2020 meeting of ACIP, Dr. Matthew Hepburn from Operation Warp 
Speed spoke about the operation, but provided very few details on what is 
actually going on.170  While there is a need to protect companies’ trade 
secrets during vaccine production, oversight companies need information 
to do their job and the public needs information to maintain trust.171  
Operation Warp Speed must preserve transparency towards the oversight 
committees.  In an unusual move, three vaccine companies voluntarily 
published their trial protocols.172  While a laudable increase of 
transparency, publishing trial protocols is not a substitute to agencies 
sharing other information (like contract conditions).173  These committees 
need information pertaining to the vaccine development process to achieve 
a safe and effective vaccine.  
IV. MESSAGING CHALLENGES 
Public trust is crucial in a pandemic; if the state wants to impose broad-
reaching measures, it has to rely either on voluntary compliance or on very 
aggressive measures, which are costly and not always available or 
effective.174  When it comes to a vaccination program, messaging matters.  
In relation to the COVID-19 vaccine, we face at least three potential 
messaging problems:  
(1) Overselling: hyping the data, creating excessive expectations that 
will then have to be corrected, undermining trust;  
 
 
170. Murray, supra note 168. 
171. See also Diana Kwon, How the Pharma Industry Pulled Off the Pivot to COVID-19, 
THESCIENTIST (July 13, 2020), https://www.the-scientist.com/bio-business/how-the-
pharma-industry-pulled-off-the-pivot-to-covid-19-67719 (comparing how companies have 
adopted collaborative information sharing processes and responded to requests to make their 
research public). 
172. Editorial, Covid Vaccine Confidence Requires Radical Transparency, NATURE, Sept. 29, 2020, 
at 8, https://media.nature.com/original/magazine-assets/d41586-020-02738-y/d41586-020-
02738-y.pdf.  
173. Id.  
174. See Jay J. Van Bavel et al., Using Social and Behavioural Science to Support COVID-19 
Pandemic Response, 4 NATURE HUM. BEHAV. 460, 466 (2020). 
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(2) Under-sharing: not being transparent enough about what is being 
done to ensure safety; not providing people enough information about 
the process and results, so that people may mistrust even a vaccine that 
actual data shows is safe and effective;  
(3) Enabling misinformation, including by leaving false messages 
without a counter. 
We had already seen several instances of overselling vaccines by June 2020, 
with potentially bad consequences.  For example, early results published by 
Moderna, a company producing one of the vaccine candidates, led to 
headlines that strongly suggested the vaccine was effective.175  Scientists spoke 
up to caution against over extrapolating from these press releases too 
quickly.176  Among the problems with Moderna’s results was the fact that, out 
of forty-five participants in the trial, Moderna provided data on only eight 
participants who developed an antibody response, raising the question of what 
other participant data showed.177  The fact that Moderna’s executives sold 
large amounts of their stock in the company for large profits did not increase 
confidence in the results, either.178  I would add that the data has since been 
published in a peer reviewed article, the results were transparently set out—
and it looks like the hype problem did not recur with the publication of the 
actual data.179  Similarly, results from the UK vaccine trials appear to have 
 
175. Elizabeth Cohen, Early Results From Moderna Coronavirus Vaccine Trial Show Participants 
Developed Antibodies Against the Virus, CNN, https://www.cnn.com/2020/05/18/health/coronavi
rus-vaccine-moderna-early-results/index.html (May 18, 2020, 7:55 PM); Press Release, 
Moderna, Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-
1273) Against Novel Coronavirus (May 18, 2020), https://investors.modernatx.com/news-
releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-
vaccine; Helen Branswell, Vaccine Experts Say Moderna Didn’t Produce Data Critical to Assessing Covid-
19 Vaccine, STAT NEWS (May 19, 2020), https://www.statnews.com/2020/05/19/vaccine-
experts-say-moderna-didnt-produce-data-critical-to-assessing-covid-19-vaccine/.  
176. See Branswell, supra note 175; Moderna Coronavirus Vaccine – Tempering the Breathless Pharma 
Hype, SKEPTICAL RAPTOR: BLOG (May 19, 2020), https://www.skepticalraptor.com/skepticalra
ptorblog.php/moderna-coronavirus-vaccine-tempering-breathless-pharma-hype/.  
177. Branswell, supra note 175; Jonathan Gardner, More Questions Than Answers as Moderna’s 
Coronavirus Vaccine Speeds Ahead, BIOPHARMA DIVE (May 19, 2020), https://www.biopharmadive.
com/news/moderna-coronavirus-vaccine-data-more-questions/578229/. 
178. Damian Garde, Moderna Executives Have Cashed Out $89M in Shares This Year, as Stock Price 
has Soared on Vaccine Hopes, STAT NEWS (May 27, 2020), https://www.statnews.com/2020/05/27
/moderna-executives-cashed-out-shares-stock-price-soared/.  
179. See Lisa A. Jackson et. al, An mRNA Vaccine Against SARS-CoV-2 – Preliminary Report, 2020 
NEW ENG. J. MED. 1920, https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022483?articleT
ools=true.  The coverage I have seen for the article was more cautious than the first press release.  
See, e.g., Berkeley Lovelace Jr., Moderna Stock Surges after Company Announces Promising Coronavirus 
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been, initially, overstated.180  What was first touted as success in immunizing 
monkeys was later questioned because the vaccine appeared to prevent 
pneumonia in the monkeys but not infection, thus suggesting the vaccine 
would not prevent spread of disease.181  These situations—initial promising 
press releases following by dampening down—lead to loss of trust.  Dr. Paul 
Offit, a vaccine expert, described it as “science by press release,” and noted the 
risk of speaking up before there is sufficient data.182 
Another potential problem is not informing the public on how vaccine safety 
is monitored and overseen.  While vaccine experts know that multiple 
oversight committees and multiple monitoring systems to evaluate vaccine 
safety exist, the public does not—and should.183  Even in pre-pandemic times, 
not enough is made public about the extensive institutional arrangements 
surrounding vaccines.  It is not because the information does not exist; rather, 
it is likely that technical bureaucratic details do not make for a good story, even 
if they are very, very important.184  In regard to COVID-19 vaccines, too, 
more information about the process would be useful.  For instance, while Dr. 
Paul Offit mentioned publicly the existence of an NIH committee and the 
mobilization to prepare for large trials,185 the Administration has not 
publicized it, and it should.  Being upfront about the steps taken to assure the 
safety of a new vaccine would help build public confidence.  For example, a 
news release—and communication to major media companies—along the 
lines of “NIH Set up Oversight Committees for Vaccine Development.”  Similarly, “The 
 
Vaccine Trial Data, CNBC, https://www.cnbc.com/2020/07/15/moderna-stock-surges-after-
releasing-promising-coronavirus-vaccine-trial-data.html (July 15, 2020, 11:06 AM) 
180. See Sarah Newey & Paul Nuki, Doubts Over Oxford Vaccine as it Fails to Stop Coronavirus in 
Animal Trials, TELEGRAPH (May 18, 2020, 12:43 PM) https://www.telegraph.co.uk/global-
health/science-and-disease/doubts-oxford-vaccine-fails-stop-coronavirus-animal-trials/. 
181. Rachel Schraer, Coronavirus Vaccine: Macaque Monkey Trial Offers Hope, BBC NEWS 
(May 15, 2020), https://www.bbc.com/news/health-52674739; see also Andy Gregory, 
Coronavirus: Scientists Warn Oxford Vaccine May Only Offer ‘Partial Protection’ After Results of Monkey 
Trial, INDEPENDENT (May 19, 2020), https://www.independent.co.uk/news/health/corona
virus-vaccine-oxford-trials-concerns-transmission-astrazeneca-latest-a9521241.html. See generally 
Callaway, supra note 40. 
182. Gardner, supra note 177. 
183. MONICA SCHOCH-SPANA ET AL., THE PUBLIC’S ROLE IN COVID-19 VACCINATION: 
PLANNING RECOMMENDATIONS INFORMED BY DESIGN THINKING AND THE SOCIAL, 
BEHAVIORAL, AND COMMUNICATION SCIENCES 7, 9 (John Hopkins Univ. 2020), https://www.c
enterforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/200709-The-Publics-Rol
e-in-COVID-19-Vaccination.pdf. 
184. Id. at 9, 24–25. 
185. See generally Emanuel & Offit, supra note 4 (discussing NIH plans to mobilize Phase 3 
testing for some of the 10 vaccines).   
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Advisory Committee for Immunization Practices Created a Work Group and is Actively Seeing 
Vaccine Development Can Help Improve Confidence.”  Even better, openly providing 
regular updates from Operation Warp Speed to these committees—and 
posting summaries or fact sheets online about where things are in regular 
intervals—can improve transparency.  Operation Warp Speed put up one fact 
sheet, which seems updated through November 30, 2020.186  Monthly updates 
detailing the progress on government-supported companies would help.  
Companies involved in vaccine development must be transparent about 
problems that arise and steps taken to address them.  For example, in the 
high-dose group of Moderna’s trial, about 25% of recipients had a fever 
and flu-like symptoms.187  Moderna decided not to use that high dose.188  
However, that information was not included in the company’s press release, 
and was later published by journalists.189  This scenario allows for the 
appearance that problems were swept under the rug—which is not what 
happened—and creates unnecessary mistrust.  It is preferable to openly 
describe any issues.  The company—or government oversight officials—
can explain why results from a high-dose group would not, necessarily, be 
a deal breaker; a few days of flu-like symptoms might still leave a vaccine 
with a favorable risk/benefit balance.  In this case, the company has also 
already decided not to use the dose that created this risk out of an 
abundance of caution.  When AstraZeneca’s vaccine trial had an adverse 
event, data about it was only made publicly available via a leak to a 
journalist—again, raising questions about transparency.190  Open, 
transparent communication builds trust and avoids a nonissue turning into 
something those seeking to create mistrust can build on.191  There are limits: 
medical privacy may prevent giving full information, but companies need 
 
186. See Fact Sheet: Explaining Operation Warp Speed, supra note 1. 
187. Matthew Herper, He Experienced a Severe Reaction to Moderna’s Covid-19 Vaccine 
Candidate.  He’s Still a Believer, STAT NEWS (May 26, 2020), https://www.statnews.com/ 
2020/05/26/moderna-vaccine-candidate-trial-participant-severe-reaction/.  
188. See Jackson et al., supra note 179, at 11 (reporting that phase 2 and phase 3 trial will 
only go as high as 100-ug, after the 250-ug dose had two adverse events).  
189. See Herper, supra note 187 (discussing how only “tidbits” of information about the 
new vaccine are being released).  
190. Adam Feuerstein, Covid-19 Vaccine Trial Participant had Serious Neurological Symptoms, but 
Could be Discharged Today, AstraZeneca CEO Says, STAT NEWS (Sept. 9, 2020), https://www.statnews
.com/2020/09/09/astrazeneca-covid19-vaccine-trial-hold-patient-report/. 
191. Here is an example of how an anti-vaccine group took this issue and used it to create 
mistrust by misrepresenting it.  Robert F. Kennedy, Jr., Vaccine Trial Catastrophe: Moderna Vaccine 
has 20% ‘Serious’ Injury Rate in High Dose Group, CHILD.’S HEALTH DEF. (May 22, 2020), 
https://childrenshealthdefense.org/news/vaccine-trial-catastrophe-moderna-vaccine-has-
20-serious-injury-rate-in-high-dose-group/. 
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to be as transparent as possible.  It is also pointless not to do that, since real 
problems cannot be hidden.  For example, when companies have to pause 
trials, that becomes public, as happened to Johnson & Johnson in 
October.192  Finally, steps must be taken to prepare to respond to anti-
vaccine misinformation about a new vaccine.  Anti-vaccine groups already 
started preparing the ground to create mistrust, or build on natural mistrust 
for a new vaccine or as a result of the previously mentioned issues.193  While 
this is not the only type of COVID-19 misinformation being spread, it is 
part of it and it needs to be countered.  Addressing the issues above reduces 
the fertile ground available for those seeking to create mistrust.  But it is 
not enough.  Responses must point out misinformation quickly.  For 
example, anti-science groups aggressively and cleverly spread the movie, 
Plandemic, on social media.194  But responses demonstrating the movie’s 
many inaccuracies were quickly created and shared on social media.195  
While  preempting and responding to misinformation before it spreads is 
preferable, at the very least, misinformation about COVID-19 vaccines 
should not be left unanswered.  
CONCLUSION 
COVID-19 continues to turn our world upside down.  While many 
desperately await a vaccine, we as a nation should be cautious not to take 
steps that will worsen the ongoing situation and halt improvement.  
Substantive pressures to prevent harms are not the only risk.  In a recent 
editorial, Dr. Paul Offit and oncologist Zeke Emanuel sounded caution 
against potential political intervention in COVID-19 vaccine development: 
 
192. Maggie Fox, Johnson & Johnson Pauses Covid-19 Vaccine Trial after ‘Unexplained Illness’, 
CNN, https://www.cnn.com/2020/10/12/health/johnson-coronavirus-vaccine-pause-bn/in
dex.html (Oct. 13, 2020, 12:20 PM).  
193. See, e.g., Bennie Badger, FACEBOOK (May 26, 2020, 10:29 PM), https://www.facebook
.com/hu.suc/posts/10157154200392551; Hear This Well, FACEBOOK (May 23, 2020, 10:26 
AM), https://www.facebook.com/HearThisWell/posts/3213865541990895; Joshua Coleman, 
Coronavirus and What We Do Next!, FACEBOOK (Mar. 18, 2020), https://www.facebook.com/117
2767973/videos/10221388003307534/.  
194. Renee DiResta & Isabella García-Camargo, Virality Project (US): Marketing Meets 
Misinformation, STAN. UNIV.: INTERNET OBSERVATORY (May 26, 2020), https://cyber.fsi.stanfor
d.edu/io/news/manufacturing-influence-0?fbclid=IwAR39LlFmXSHY6rQ36c804KOBkpIF
gSKAv_eKJojooAI81KvJ3GMsbQ91ExY.  
195. See Liz Ditz, Judy Mikovits: Not a Reliable Source of Information on COVID19, Vaccines, or 
Anything in Science, I SPEAK OF DREAMS (May 8, 2020), https://lizditz.typepad.com/i_speak_of_d
reams/2020/05/judy-mikovits-not-a-reliable-source-of-information-on-covid19-vaccines-or-
anything-in-science.html (containing a list of responses). 
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. . .  the F.D.A. could issue an Emergency Use Authorization for one or more 
vaccines. . . 
An emergency authorization would allow Mr. Trump to hold his news conference and 
declare victory. But like President George W. Bush’s “Mission Accomplished” 
proclamation, it has the potential to be a travesty. Millions of vaccines could be 
distributed without proof that the vaccine can prevent disease or transmission.196 
. . .  
Thousands of Americans have already died as Donald Trump has perpetually 
postponed effective public health interventions and made poor therapeutic 
recommendations.  We must be on alert to prevent him from corrupting the rigorous 
assessment of safety and effectiveness of Covid-19 vaccines in order to pull an October 
vaccine surprise to try to win re-election.197 
President-Elect Joe Biden’s COVID-19 plan emphasizes the need for expertise 
and states that his Administration will:  “Put scientists in charge of all decisions 
on safety and efficacy; publicly release clinical data for any vaccine the FDA 
approves; and authorize career staff to write a written report for public review 
and permit them to appear before Congress and speak publicly 
uncensored.”198  Sticking to this statement can help assuage concerns, but the 
timing is tricky: the new Administration will not come in until January, and 
companies may well move to request an Emergency Use Authorization before 
that.199 Practical and political pressures can lead to inappropriately rushed 
vaccine development—and can backfire.  The United States has a remarkable 
system for testing vaccines and monitoring their safety, and we should let it 
work in this case, too.  Adjustments can be made without forgoing safety, and 
we should make sure we are, indeed, not sacrificing safety or effectiveness. 
 
 
196. Emanuel & Offit, supra note 4. 
197. See id. (concerning politicizing the process). 
198. The Biden-Harris Plan to Beat Covid-19, BIDEN-HARRIS TRANSITION https://buildbackb
etter.com/priorities/covid-19/ (last visited Dec. 2, 2020). 
199. Lisa Schnirring, Feds Update Vaccine Arrival Amid Record US Covid-19 Rise, UNIV. OF 
MINN. CTR. FOR INFECTIOUS DISEASE RSCH. & POL’Y (Nov. 13, 2020) https://www.cidrap.umn
.edu/news-perspective/2020/11/feds-update-vaccine-arrival-amid-record-us-covid-19-rise. 
